The objective of this study was to assess the antihypertensive effect and the trough to peak (T:P) ratio of lisinopril and captopril, in patients with essential hypertension.
Introduction
Studies using 24-h ambulatory blood pressure monitoring (ABPM) have demonstrated that the 24-h mean BP is more strongly associated with several signs of target organ damage such as left ventricular mass than traditional sphygmomanometry. In addition, reduction in 24-h BP with antihypertensive treatment correlates with reductions in target organ damage. 1 Thus, the therapeutic requirement for an antihypertensive drug is to provide 24-h control of BP.
It has been proposed that the efficacy of antihypertensive drugs should be assessed by the trough to peak (T:P) ratio, calculated as the ratio between the BP reduction at the end of the dose interval (trough) relative to the reduction at peak. A T:P ratio of 0.5-0.66 is considered to be a minimum requirement to prove that a drug is suitable for its dosing interval. 2 Such a ratio may prevent administration of inappropriately large doses of an antihypertensive drug in order to extend the duration of action to 24 h, risking hypotension due to a pronounced peak effect.
In recent years the dose interval of many antihy-pertensive drugs, especially calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors has been assessed using the T:P ratio derived from BP measurements obtained during ABPM. 3 These studies suggested that not all drugs advised for once-daily use comply with the FDA recommendation that T:P ratio should be greater than 0.5. For these agents it appears that a 24-h dosing interval is too long and that they should be given in divided doses.
The aim of this trial was to compare the antihypertensive effects and evaluate the T:P ratio of two different ACE inhibitors, namely captopril, a shortacting agent administered twice-daily, and lisinopril, a drug with a relatively long period of action administered once daily.
Material and methods

Patients
The trial involved six centres throughout Spain. Informed consent and protocol approval by the local Ethics Committee was obtained in each of the participating hospitals.
The study was in 69 patients (42 males, 27 females; mean age 47.7 ± 10 years) with essential hypertension, defined as an untreated office diastolic BP (DBP) у90 mm Hg and Ͻ115 mm Hg by sphygmomanometer. All patients were between 18 and 65 years of age, and were previously untreated or had discontinued antihypertensive therapy 2 weeks before entering the placebo phase. Patients were not selected on the basis of previous BP response with any specific drug, especially ACE inhibitors. Subjects were excluded if they had secondary hypertension, significant cardiovascular, renal or liver disease, known intolerance to the study drugs or to drugs of the same class. After a 2-week placebo run-in period the patients underwent a 24-h ABPM and were randomised to either active drug if the mean DBP during daytime (07.00-23.00 hours) was Ͼ85 mm Hg and the sitting office DBP by sphygmomanometry was 90-114 mm Hg.
A total of 115 patients recruited from the hypertension clinics entered the placebo phase of the study and 69 proceeded to randomised treatment and completed the study. Forty-six patients who did not enter the randomisation phase had mean daytime diastolic ABPM below 85 mm Hg after the placebo period.
Methods
A parallel study design was used. Following 2 weeks on placebo the patients were randomised to either lisinopril 20 mg once daily or captopril 50 mg twice daily for 4 weeks. At baseline and again after 4 weeks of active treatment, office BP and 24-h ABPM were carried out on a working day using an automatic non-invasive device (SpaceLabs model 90207, Redmond, WA, USA). Office BP was measured three times at 5-min intervals in the sitting position by a mercury sphygmomanometer and 1st and 5th Korotkoff sounds were used to identify systolic and diastolic BP respectively. Measurements were made before the morning dose of the study medications, 24 ± 2 h after the previous dose of lisinopril and 12 h after the previous dose of captopril. The ABPM monitor was applied between 09.00 and 10.00 hours and the medication was taken by the patients 20 min after fitting the monitor.
Statistical analysis
In order to minimise the variability inherent to ambulatory recording, peak BP response was derived from an average reading over 2 h during the period of maximum plasma drug concentration (3-6 h after dosing), selecting the hour with the maximal BP fall and the adjacent hour in which the second highest fall was present. 4 Trough response was the reduction in BP obtained during the hour before dosing. For each active drug the T:P ratio was calculated after subtraction of the placebo effect at peak and trough from that of each active drug. T:P ratio was determined individually for each patient. For each drug, the final T:P ratio was calculated as the mean ± s.d. of the individual ratios.
We calculated T:P ratio in the treatment groups as a whole and also in subgroups who achieved control of BP (office BP Ͻ140 mm Hg, designated CP), patients who were defined as responders (office DBP decreased Ͼ5 mm Hg on active treatment, designated RP), and also in responders measured during ABPM using the criteria of Waeber et al
Comparisons of means were done using the paired (with groups) and unpaired (between groups) t-test. Percentages were compared by 2 analysis.
Results
Thirty-six patients were randomised to lisinopril and 33 to captopril. Both treatment groups presented similar characteristics of age, gender, body mass index, duration of hypertension and BP before and after the placebo period (Tables 1 and 2 ).
Effects on BP
The mean office BP after 4 weeks captopril treatment was 137.5 ± 14.6/89.3 ± 9.9 mm Hg and for the lisinopril group 131.5 ± 13.9/84.5 ± 10 mm Hg (P Ͻ 0.01). After 4 weeks of treatment, the number and percentage of patients controlled (CP group) with lisinopril (n = 27, 75%) was significantly higher than those controlled with captopril (n = 16, 44.4%, P Ͻ 0.001). Table 3 shows the BP values obtained during a 24h-ABPM period after both the run-in period with placebo and the treatment with the two drugs. We observed significant reductions of all indices of BP derived from ABPM (24 h, daytime and night-time average BP) during active treatment. No significant differences between the effect of captopril and lisinopril on BP were observed. Heart rate remained unchanged during the treatment with both drugs. The proportion of responder patients using the Waeber criteria (MRP group) was 61% in the lisinopril group and 39% the patients treated with captopril (P Ͻ 0.05).
T:P ratio
Peak and trough DBP were similar in patients treated with lisinopril (peak, 77 ± 14; trough 85 ± 15 mm Hg) and captopril (peak, 82 ± 10; trough, 90 ± 10 mm Hg). Table 4 shows the diastolic T:P ratio for lisinopril and captopril in the whole group, and in subgroups as defined above. Twelve patients in each group had T:P ratios below 50%. The diastolic T:P values of lisinopril tended to be higher but not significantly different than those of captopril when considering the patients as a whole and when the calculations were made taking into account the ABPM responders and those with an optimal control of BP. Similar data were obtained using median rather than mean T:P ratios. 105 ± 9 9 6 ± 14*** 108 ± 8 101 ± 9*** NS HR 24 h 75 ± 8 7 6 ± 9 ns 79 ± 8 7 8 ± 9 ns NS SBP daytime 141 ± 13 129 ± 17*** 144 ± 8 135 ± 12*** NS DBP daytime 93 ± 7 9 9 ± 14*** 95 ± 6 8 9 ± 9*** NS MBP daytime 109 ± 9 8 4 ± 12*** 112 ± 7 104 ± 9*** NS HR daytime 79 ± 9 8 1 ± 11 ns 83 ± 8 8 2 ± 11 ns NS SBP night-time 130 ± 15 117 ± 18*** 133 ± 13 121 ± 12*** NS DBP night-time 82 ± 10 73 ± 14*** 83 ± 6 7 6 ± 8*** NS MBP night-time 99 ± 12 82 ± 15*** 100 ± 8 9 1 ± 9*** NS HR night-time 68 ± 8 6 5 ± 9* 72 ± 11 69 ± 8* NS *P Ͻ 0.05; ***P Ͻ 0.001, active drugs vs placebo; a lisinopril vs captopril. NS: no statistical differences. 
Discussion
The main finding of this study is that both lisinopril 20 mg once-daily, and captopril 50 mg twice-daily, when administered to patients with mild to moderate essential hypertension, effectively reduced BP and had diastolic T:P ratios greater than 0.50, thus fulfilling FDA guidelines.
2 Both drugs were highly effective in reducing the office BP as well as those obtained by ABPM. However, office BP at the end of the treatment periods was lower, and the percentages of patients controlled according to the conventional criteria (office BP Ͻ140/90 mm Hg) and responders according the ABPM criteria were higher with lisinopril than with captopril. The results for lisinopril were similar to those reported by other investigators 6 and can be explained by the high trough effect of the dose of 20 mg of lisinopril 7 even administered once-a-day in comparison with 50 mg captopril after 12 h.
It has been suggested that the calculation of T:P ratio can be erroneously influenced if non-responder patients to the drug are included, because the nonresponders will cause high variability in the T:P ratios. This may lead to high ratios of no clinical significance because the consequent dilution bias underestimates the magnitude of the BP decrease and therefore overestimates the T:P ratio. 3 For this reason it has been recommended that the T:P ratio should be calculated only in those patients responding to active treatment. 8 In the present study, diastolic T:P ratios calculated in responders to either lisinopril or captopril were similar to those of the total group. In patients controlled with either drug the diastolic T:P ratios were similar to those of the total group. We did not find any significant difference in the T:P ratio of the non-controlled patients (0.70 and 0.65 for lisinopril and captopril, respectively) and in well-controlled patients (0.78 and 0.73) suggesting that this is not an important limitation in this study.
We did not take account of patients' responses to placebo treatment because their inclusion may bias both group and individual T:P ratio evaluation. 9 The T:P ratio was calculated from BP derived from ABPM, whereas the guidelines proposed by FDA are based on casual assessment of BP in the clinic. 2 The advantages and disadvantages of using ABPM to calculate this ratio has been discussed by Zanchetti et al 10 and we agree that this method is useful in measuring the T:P ratio of an antihypertensive drug even when problems of calculating peak effect are taken into account.
In conclusion, the present study demonstrates that treatment of patients with essential hypertension with either lisinopril 20 mg daily or captopril 50 mg twice-daily for 4 weeks causes a significant decrease of both office and ambulatory BP. The percentage of patients well controlled with lisinopril by office measurement was higher than those controlled with captopril but this was not the case in the ABPM studies. Calculated diastolic T:P ratios were over 0.6 with both drugs. Thus, 20 mg lisinopril once-daily and 50 mg captopril twice-daily are both suitable for treatment of patients with essential hypertension, using both T:P ratio and absolute fall in BP as the criteria.
